Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results
09 March 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2015.
Clearside Biomedical, Inc. Announces Appointment of Richard J. Croarkin to the Board of Directors
29 February 2016
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that Richard J. Croarkin has been appointed to Clearside’s Board of Directors. Mr. Croarkin is the former Senior Vice President of Finance, Chief Financial Officer & Corporate Strategy Officer of Alcon, Inc. and brings extensive global financial experience from working for diverse companies, including Nestlé Health Science S.A., Pepsico Incorporated and AMAX, Inc.
Swiss company Ferring Pharma to set up a manufacturing and R&D base in Hyderabad
12 February 2016
Switzerland-based specialty pharmaceuticals group Ferring Pharma is planning to set up a manufacturing plant in the upcoming Pharma City located near Hyderabad. While the company refused to give a number to the investments at this stage, the government sources indicated that it could be anywhere from $100- $250 mn.
Atlas Genetics Gains CE Approval for First Product
08 February 2016
Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has received approval to CE Mark its Chlamydia trachomatis (CT) test to be launched on the Company's io® platform. By meeting the requirements of the IVD Directive (98/79/EC), the CT test is now cleared for sale within the European Union.
Avera Medical Group and Epic Sciences collaborate on cancer precision medicine clinical trials
28 January 2016
Epic Sciences, Inc. and Avera Medical Group announced today a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials.
GenePool from Station X to Help Epic Sciences Analyze Circulating Tumor Cell Data
25 January 2016
Station X, Inc., a pioneer in solving big data analytics and platform integration challenges for customers engaging in genomics-based clinical research and medical applications, today announced that Epic Sciences will use its GenePool® platform to facilitate data interpretation and collaboration with biopharmaceutical companies developing companion diagnostics based on the company’s innovative circulating tumor cell (CTC) technology.
Allan L. Shaw Joins Syndax Pharmaceuticals As Chief Financial Officer
20 January 2016
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced today that the Company has appointed Allan L. Shaw as Chief Financial Officer, Treasurer and Secretary. Mr. Shaw joins Syndax with more than 20 years of experience as a chief financial officer, industry executive and independent board member of public companies.
Epic Sciences Receives CAP Accreditation
11 January 2016
Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory. The CAP Laboratory Accreditation Program is recognized bythe United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.
Clearside Biomedical, Inc. Files Registration Statement for Proposed Initial Public Offering
08 January 2016
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission related to Clearside’s proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not been determined.
Sherer and White to Receive 2016 Georgia Bio Industry Growth Awards
08 January 2016
Todd Sherer, PhD, Associate Vice President & Executive Director of the Emory University Office of Technology Transfer, and Daniel White, President and CEO of Clearside Biomedical Inc. are the recipients of the 2016 Georgia Bio Industry Growth Awards.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024